Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

被引：0
|
作者：
Li, Nanxin [1 ]
Wilson, Koo [2 ]
Botteman, Marc [3 ]
Nicoloso, Daniel [3 ]
Krishnan, Sangeeta [1 ]
Su, Jun [1 ]
机构：
[1] Bioverativ, Waltham, MA USA
[2] Swedish Orphan Biovitrum SOBI, Stockholm, Sweden
[3] Pharmerit Int, Bathesda, MD USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-114993
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3520
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
    Powell, Jerry S.
    Josephson, Neil C.
    Quon, Doris
    Ragni, Margaret V.
    Cheng, Gregory
    Li, Ella
    Jiang, Haiyan
    Li, Lian
    Dumont, Jennifer A.
    Goyal, Jaya
    Zhang, Xin
    Sommer, Jurg
    McCue, Justin
    Barbetti, Margaret
    Luk, Alvin
    Pierce, Glenn F.
    BLOOD, 2012, 119 (13) : 3031 - 3037
  • [42] Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
    Peters, R. T.
    Toby, G.
    Lu, Q.
    Liu, T.
    Kulman, J. D.
    Low, S. C.
    Bitonti, A. J.
    Pierce, G. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (01) : 132 - 141
  • [43] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    BLOOD, 2014, 123 (03) : 317 - 325
  • [44] Immune tolerance treatment with recombinant factor VIII Kogenate(R)
    Batlle, J
    Lopez, MF
    Brackmann, HH
    Gaillard, S
    Goudemand, J
    Humbert, J
    deMoerloose, P
    Maass, E
    MauzKorholz, C
    Sultan, Y
    Stieltjes, N
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2643 - P2643
  • [45] Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein Treatment of hemophilia A
    Villarreal-Martinez, Laura
    Zamora-Martinez, Paola Lizeth
    DRUGS OF THE FUTURE, 2022, 47 (10) : 711 - 714
  • [46] Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products
    Iorio, A.
    Krishnan, S.
    Myren, K-J
    Lethagen, S.
    McCormick, N.
    Karner, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 324 - 324
  • [47] Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors
    Rocino, Angiola
    Santagostino, Elena
    Mancuso, Maria Elisa
    Mannucci, Pier Mannuccio
    HAEMATOLOGICA, 2006, 91 (04) : 558 - 561
  • [48] Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16+ NK cell activation
    Lagasse, H. A. Daniel
    Ou, Jiayi
    Sauna, Zuben E.
    Golding, Basil
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [49] FACTOR CONSUMPTION FOR PROPHYLAXIS AND TREATMENT OF BLEEDING: RECOMBINANT FACTOR IX FC FUSION PROTEIN COMPARED WITH CONVENTIONAL RECOMBINANT FACTOR IX
    Iorio, A.
    Krishnan, S.
    Myren, K.
    Lethagen, S.
    McCormick, N.
    Kamer, P.
    VALUE IN HEALTH, 2015, 18 (07) : A660 - A660
  • [50] Higher immune tolerance (IT) success rate with monoclonal factor VIII (mFVIII) when compared to recombinant (rFVIII): An analysis of the North American Immune Tolerance Registry (NAITR).
    DiMichele, DM
    Kroner, BL
    BLOOD, 2000, 96 (11) : 266A - 266A
12345